로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > KIR2DL3

KIR2DL3

요약

Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:P58.2 MHC Class-I Specific NK Receptor,MHC Class I NK Cell Receptor,CD158b2 Antigen,KIR-K7b,KIR-K7c,KIR2DS5,CD158b,KIR2DL,NKAT2A,NKAT2B,GL183,NKAT,P58,Receptors, KIR2DL3,Cl-6,Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3,Natural Killer Cell Inhibitory Receptor KIR2DL3,Natural Killer Associated Transcript 2,p58.2 MHC class-I-specific NK receptor,Natural killer-associated transcript 2,NKAT-2,NKAT2,p58 natural killer cell receptor clone CL-6,Killer inhibitory receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
KI3-H5258 Human Human KIR2DL3 / CD158b2 / NKAT-2 Protein, Fc Tag (MALS verified)
KI3-H5258-structure
KI3-H5258-sds

일부의 생물활성 데이터

KI3-H5258-SPR
 KIR2DL3 SPR

Biotinylated Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL3, Fc Tag (Cat. No. KI3-H5258) with an affinity constant of 2.40 μM as determined in a SPR assay (Biacore 8K) (Routinely tested)

KI3-H5258-MALS-HPLC
KIR2DL3 MALS images

The purity of Human KIR2DL3, Fc Tag (Cat. No. KI3-H5258) is more than 90% and the molecular weight of this protein is around 108-132 kDa verified by SEC-MALS.

Synonym Name

CD158b2

Background

Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as  CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Leukemia; Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Hodgkin Disease; Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute Details
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Leukemia; Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Hodgkin Disease; Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totop